China Vaccine Market Report 2023 to 2027 - Featuring Walvax Biotechnology, Beijing Tiantan Biological Products, Sinovac Biotech and Shenzhen Kangtai Biological Products Among Others - ResearchAndMarkets.com
Retrieved on:
Tuesday, January 31, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, Administration, Vaccination, Meningitis, Attenuated vaccine, Meningococcal disease, Rabies, MPSV4, Conjugate vaccine, Safety, Sinovac Biotech, PCV13, Expanded Program on Immunization, Infant, EPI, Sinopharm Group, Birth rate, Category, Parent, Pneumococcal polysaccharide vaccine, Forecasting, Policy, DTP, COVID-19, Category 2, R, Ageing, Pharmaceutical industry, Vaccine, Haemophilus, Immunization
As a result, China has drawn significant attention to the vaccine industry to play a representative role.
Key Points:
- As a result, China has drawn significant attention to the vaccine industry to play a representative role.
- In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players.
- Meningococcal Meningitis, Pneumococcal, and DTP Vaccine market are expected to control a significant portion of China's vaccine market.
- The major players covered in the report are Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd.